Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Objective Transitions to biosimilars are common to reduce the cost burden of biologics. While brand changes can be daunting for patients, few studies have explored patients’ experiences with the transitioning process. This study examined rheumatology patients’ experiences with a mandatory nationwide...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11634 |